Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: varicella zoster

Upadacitinib Promising for RA in Phase 3 Study

Michele B. Kaufman, PharmD, BCGP  |  December 5, 2017

In a recent study, upadacitinib proved safe and effective to treat rheumatoid arthritis in patients with inadequate responses to conventional synthetic DMARDs…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Rheumatoid Arthritis (RA)upadacitinib

GSK Wins U.S. Shingles Vaccine Approval, U.K. Nod for Gene Therapy

Ben Hirschler  |  October 23, 2017

LONDON (Reuters)—GlaxoSmithKline has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year. It also secured a recommendation from U.K. cost authorities for a $700,000 gene therapy for so-called “bubble boy” disease—a step forward for the field of fixing faulty…

Filed under:Conditions Tagged with:FDA approvalshinglesShingrixU.S. Food and Drug Administration (FDA)vaccine

GlaxoSmithKline’s Shingles Vaccine Gets Approval in Canada

Reuters Staff  |  October 16, 2017

(Reuters)—Canadian health regulators have approved GlaxoSmithKline’s shingles vaccine, the company said on Friday.1 Shingrix, the British pharma company’s shingles vaccine for people aged 50 years or older, was unanimously recommended for approval by a U.S. Food and Drug Administration (FDA) advisory panel last week. Older people are most at risk of an outbreak of shingles,…

Filed under:Drug Updates Tagged with:GlaxoSmithKlineshinglesvaccinationvaricella zoster virus

Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity

Reuters Staff  |  August 29, 2017

NEW YORK (Reuters Health)—Tofacitinib begun two to three weeks after live zoster vaccination does not impair immunogenicity, and vaccination appears to be safe in patients with pre-existing varicella zoster virus (VZV) immunity, researchers report. Patients with rheumatoid arthritis (RA) are about twice as likely as healthy adults to develop herpes zoster, or shingles, and the…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis & RheumatologyshinglesTofacitinibvaccinevaricella zoster virus

Fellows Forum Case Report: Neuromyelitis Optica

Atul Kapila, MD, Tayseer Haroun, MBBS, & Jayanth Doss, MD  |  April 19, 2017

Case Presentation The patient was a 42-year-old African American female diagnosed with systemic lupus erythematosus (SLE) based on the findings of polyarthritis, malar and discoid rash, fatigue, positive double-stranded DNA (dsDNA) ribonucleoprotein and Smith antibodies, and low serum complement levels. Her SLE had been well controlled on hydroxychloroquine 400 mg daily, oral methotrexate 25 mg…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:case reportcentral nervous systemClinicalDevic's diseaseDiagnosiseyeFellowsFellows Foruminflammatory syndromeneuromyelitis opticaoutcomerheumatologyTreatmentvision

Metagenomic Deep Sequencing for Uveitis Enhances Traditional Diagnostic Testing

Thuy Doan, MD, PhD, Michael R. Wilson, MD, MAS, & Joseph L. DeRisi, PhD  |  March 20, 2017

Throughout their training and practice, physicians become adept at pattern recognition as a means to efficiently connect and synthesize seemingly disparate laboratory, physical exam, and radiologic and historical findings into a coherent theory for what likely ails the patient sitting in front of them. This inductive method of reasoning is necessary because, based on these…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:diagnostichypothesis-freeinflammatory syndromeintraocular infectionmetagenomic deep sequencingpatient carerheumatologistrheumatologyTestUveitis

Not All Infectious Microorganisms Malign Human Immune System

Simon M. Helfgott, MD  |  November 16, 2016

Which came first? The infectious microorganism or a host’s immune resistance against it? Through the millennia, a raging battle has pitted the hordes of infectious agents surrounding us against, arguably, the most complex biologic structure ever created, the finely tuned human immune system. The stakes are high for both sides. For the infectious agent, an…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:autoimmunityDiseaseessential mixed cryoglobulinemiaHepatitis C virushuman microbiomeImmune SystemInfectionmicroorganism

Research in Temporal Arteritis Suggests Link with Infection, Autoimmune Disease

Shamik Bhattacharyya, MD, MS  |  November 16, 2015

Temporal arteritis was first described by Sir Jonathan Hutchinson in 1890 in an elderly retired gentleman’s servant who developed red, painful streaks on his temples and was found to have bilaterally swollen temporal arteries with feeble pulses.1 Sir Hutchinson disputed the suggestion that the red streaks were caused by the man’s hat and, instead, called…

Filed under:ConditionsOther Rheumatic ConditionsResearch RheumVasculitis Tagged with:Autoimmune diseaseCauseGiant Cell ArteritisInfectionResearchrheumatologytemporal arteritisvaricella zoster virus

Rheumatology Drug Updates

Michele B. Kaufman, PharmD, BCGP  |  March 1, 2013

Information on new approvals and medication safety that rheumatologists need to know

Filed under:Drug Updates Tagged with:ApprovalsDrugsFDAPipeline

Meet the Challenge of Primary CNS Vasculitis

Carlo Salvarani, MD, Robert D. Brown, Jr., MD, MPH, and Gene G. Hunder, MD  |  September 1, 2011

Diagnosis and treatment of this rare and poorly understood condition

Filed under:ConditionsPractice SupportQuality Assurance/ImprovementVasculitis Tagged with:central nervous systemDiagnostic CriteriaPathogenesispatient careTreatmentVasculitis

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences